Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

di Decaens, Thomas, Barone, Carlo, Assenat, Eric, Wermke, Martin, Fasolo, Angelica, Merle, Philippe, Blanc, Jean-Frédéric, Grando, Véronique, Iacobellis, Angelo, Villa, Erica, Trojan, Joerg, Straub, Josef, Bruns, Rolf, Berghoff, Karin, Scheele, Juergen, Raymond, Eric, Faivre, Sandrine
Pubblicato in Br J Cancer (2021)

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

di van Bussel, Mark T. J., Awada, Ahmad, de Jonge, Maja J. A., Mau-Sørensen, Morten, Nielsen, Dorte, Schöffski, Patrick, Verheul, Henk M. W., Sarholz, Barbara, Berghoff, Karin, El Bawab, Samer, Kuipers, Mirjam, Damstrup, Lars, Diaz-Padilla, Ivan, Schellens, Jan H. M.
Pubblicato in Br J Cancer (2020)

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

di Ryoo, Baek-Yeol, Cheng, Ann-Li, Ren, Zhenggang, Kim, Tae-You, Pan, Hongming, Rau, Kun-Ming, Choi, Hye Jin, Park, Joong-Won, Kim, Jee Hyun, Yen, Chia Jui, Lim, Ho Yeong, Zhou, Dongli, Straub, Josef, Scheele, Juergen, Berghoff, Karin, Qin, Shukui
Pubblicato in Br J Cancer (2021)